Guangzhou Innogen Pharmaceutical (HKG:2591) said its H shares have been added to both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Monday, according to a same-day bourse filing.
The inclusion will allow mainland investors to trade the company's H shares through the Shanghai and Shenzhen stock exchanges.
The board said the move is expected to broaden the firm's investor base, boost liquidity, and strengthen its profile in the capital market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments